Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Capital Expenditures (2019 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Capital Expenditures for 6 consecutive years, with $49000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 308.33% to $49000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $333000.0 through Dec 2025, up 1180.77% year-over-year, with the annual reading at $333000.0 for FY2025, 1180.77% up from the prior year.
  • Capital Expenditures hit $49000.0 in Q4 2025 for Eton Pharmaceuticals, down from $284000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $284000.0 in Q3 2025 to a low of $2000.0 in Q3 2021.
  • Historically, Capital Expenditures has averaged $44777.8 across 4 years, with a median of $12000.0 in 2022.
  • Biggest five-year swings in Capital Expenditures: tumbled 90.91% in 2021 and later soared 308.33% in 2025.
  • Year by year, Capital Expenditures stood at $4000.0 in 2021, then surged by 200.0% to $12000.0 in 2022, then changed by 0.0% to $12000.0 in 2024, then soared by 308.33% to $49000.0 in 2025.
  • Business Quant data shows Capital Expenditures for ETON at $49000.0 in Q4 2025, $284000.0 in Q3 2025, and $12000.0 in Q4 2024.